Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP

International Journal of Hematology

Volumn 97, Issue 3, 2013, Pages 397-402

  Oh, Min Young ^a   Chung, Joo Seop ^a   Song, Moo Kon ^a   Shin, Ho Jin ^a   Lee, Ho Sup ^b   Lee, Sang Min ^c   Lee, Gyeong Won ^d   Lee, Su Ee ^e  

^a Pusan National University School of Medicine   (South Korea)

^b Kosin University   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Gyeongsang National University   (South Korea)

^e Dong A Medical Center   (South Korea)

Author keywords

Diffuse; Large b cell; Lymphoma; Tumor burden

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R CHOP PROTOCOL; R-CHOP PROTOCOL; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; WALDEYER RING; YOUNG ADULT; CANCER STAGING; DISEASE FREE SURVIVAL; MORTALITY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; RADIOPHARMACEUTICALS; SURVIVAL RATE; TUMOR BURDEN; VINCRISTINE;

EID: 84887588744     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1282-3     Document Type: Article

References (28)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histological subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-95.
2. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-18.
3. Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation- A population-based study of 1575 cases. Br J Haematol. 2004;124:151-9.
4. Lopez-Guillermo A, Colomo L, Jimenez M, Bosch F, Villamor N, Arenilas L, Muntanola A, Montoto S, Gine E, Colomer D, Bea S, Campo E, Monsterrat E. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol. 2005;23: 2797-804.
5. d'Amore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup J. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer. 1991;27:1201-8.
6. Krol AD, Le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM. Waldeyer's ring lymphomas: A clinical study from the Comprehensive Cancer Center West population based NHL Registry. Leuk Lymphoma. 2001;42:1005-13.
7. Ezzat AA, Ibrahim EM, El-Weshi AN, Khafaga YM, AlJurf M, Martin JM, Ajarim DS, Bazarbashi SN, Stuart RK, Zucca E. Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. Head Neck. 2001;23:547-58.
8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Neste EVD, Salles G, Gaulard P, Reyes F, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-42.
9. Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP, Gorges R, Nowrousian MR, Bockisch A, Debatin JF. FDGPET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325-9.
10. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, de Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-92.
11. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, editors. WHO classification of tumors: pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 171-4.
12. Qi Shu-Nan, Li Ye-Xiong, Wang Hua, Wang Wei-Hu, Jin Jing, Soung Young-Wen, Wang Shu-Lian, Liu Yue-Ping, Zhou Li- Qiang, Zi-Hao Yu. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer Ring versus lymph node presentation. Cancer. 2009;115:4980-9.
13. Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, Lee GW, Kim SJ, Lee SM, Chung DS. Clinical significance of metabolic tumor volume by PET/CT in stage II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697-703.
14. Song MK, Chung JS, Shin HJ, Moon JH, Lee JO, Lee HS, Lee SM, Lee GW, Lee SE, Kim SJ. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci. 2012;103:477-82.
15. Lartizien C, Kinahan PE, Swensson R, Comtat C, Lin M, Villemagne V, Trebossen R. Evaluating image reconstruction methods for tumor detection in 3-dimensional whole-body PET oncology imaging. J Nucl Med. 2003;44:276-90.
16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RE, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeeak A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86.
17. Pileri SA, Dirnhofer S, Went Ph, Ascani S, Sabattini E, Marafioti T, Tzankov A, Leoncini L, Falini B, Zinzani PL. Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology. 2002;41: 482-509.
18. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH, de Jong D, Maaratense E, Schuuring E, Kluin PM. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152-62.
19. Muramatsu M, Akasaka T, Kadowaki N, Ohno H, Yamabe H, Edamura S, Doi S, Mori T, Okuma M, Fukuhara S. Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms: comparison with lymphomas associated with BCL2 rearrangement. Br J Haematol. 1996;93:911-20.
20. Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K, Guldberg P. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity. Blood. 1998;92:3018-24.
21. Wohlfart S, Sebinger D, Gruber P, Buch J, Polgar D, Krupitza G, Rosner M, Hengstschlager M, Raderer M, Chott A, Mullauer L. FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. Am J Pathol. 2004;164:1081-9.
22. De Pena CA, Van Tassel P, Lee YY. Lymphoma of the head and neck. Radiol Clin North Am. 1990;28:723-43.
23. Jacobs C, Hoppe RT. Non-Hodgkin's lymphomas of head and neck extranodal sites. Int J Radiat Oncol Biol Phys. 1985;11:357-64.
24. Endo S, Kida A, Sawada U, Sugitani M, Furusaka T, Yamada Y, Iida H, Sakai F, Shigihara S, Niwa H, Yamazaki T, Kura Y, Kikuchi K. Clinical analysis of malignant lymphomas of tonsils. Acta Otolaryngol Suppl. 1996;523:263-6.
25. Hoppe RT, Burke JS, Glatstein E, Kaplan HS. Non-Hodgkin's lymphoma: involvement of Waldeyer's ring. Cancer. 1978;42: 1096-104.
26. Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer. 1984;53: 2515-24.
27. Harabuchi Y, Tsubota H, Ohguro S, Himi T, Asakura K, Kataura A, Ohuchi A, Hareyama M. Prognostic factors and treatment outcome in non-Hodgkin's lymphoma of Waldeyer's ring. Acta Oncol. 1997;36:413-20.
28. Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, Hashimoto C, Tamura K, Sato K, Ishigatsubo Y. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012;188:4166-72.